Sequences were preprocessed based on the following criteria: the sequences containing more than 5 ambiguous bases and sequences with more than 8 polymers were culled. All chimeric reads were found and removed using UCHIME (Edgar et al., 2011). The reference database used for chimera removal was RDP.gold (https://rdp.cme.msu.edu) (Release 11, Update 4; May 26, 2015). Undesirable lineages (Mitochondria-Chloroplast-Eukaryotes-Archaea) were removed using the Naïve Bayes classifier (Wang et al., 2007). Reads with the low-quality score were removed. Singletons (reads that appear just once) were discarded. Reads were trimmed at a fixed length. OTU selection was performed using UPARSE (Edgar, 2013). After finding OTUs or centroids, all the reads were mapped to OTUs using an identity threshold of 97%. An abundance table was constructed that included all the OTUs and their abundance for each sample. The OTUs were aligned to 16S reference sequence database GreenGenes (http://greengenes.lbl.gov) using the RDP classifier (Wang et al., 2007), and a taxonomic ID was generated for each OTU.
SUPPLEMENTAL FIGURES
. Polyp dataset rarefaction plots for biopsy, stool, and rectal swab samples All plots have reached a plateau, which means sequencing depth is acceptable.
Figure S2. Alpha diversity: results for biopsy, home stool, and rectal swab samples
For the diversity indices of Shannon, Simpson, invSimpson, and observed species (sobs), the diversity was significantly different between polyp-Y and polyp-N groups except for shannon diversity index that was just significantly different in the bioposy dataset.
Figure S3. Beta diversity: UniFrac PCoA plots of the biopsy, home stool, and rectal swab samples
PERMANOVA test showed that weighted UniFrac distances in the biopsy group were significantly different between polyp-Y and polyp-N groups. ANOSIM couldn't find any significant difference between the polyp-Y and polyp-N groups in none of the datasets. The axes are principal components.
ANOSIM, analysis of similarities; BS, biopsy samples; HS, home stool samples; PERMANOVA, permutational multivariate analysis of variance; PCoA, principal coordinates analysis; Polyp-N, polypnegative group; Polyp-Y, polyp-positive group; SS; rectal swab samples; UniFrac, unique fraction. There are many structural differences among these studies including sample type (tissue, stool, and rectal swab), population (various genetic background, different geography), and technical differences (Sequencing method, 16S rRNA primer); these differences can affect the findings of these reports and they may not be readily comparable.
CRC, colorectal cancer; N/A, not available. The top tables show validation results of the classifiers produced using all OTUs. The middle tables used just the informative OTUs as classification features. The bottom tables are the result of applying the second classifier on the test dataset. Classifiers perform better when informative OTUs are used as classification features. 
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Correctly classified rectal swab test samples are 81.8% of the samples.
Polyp-N, polyp-negative group; Polyp-Y, polyp-positive group; SS, rectal swab sample. 
McCoy et al. 2013
Rectal mucosa biopsy There is no consensus among various studies in the alpha diversity and bacterial abundance at phylum level for Bacteroidetes, Firmicutes, and Proteobacteria. In most of the studies, alpha diversity increased in the adenoma and cancer group. Proteobacteria has been reported to increase in the adenoma/CRC state in most of the studies. Ad, Adenoma; CRC, colorectal cancer; H, Healthy; N/A, not available; N/S, not significant. Differential taxa Fusobacterium: ten of seventeen studies summarized in Table S12 reported an increase of Fusobacterium abundance in cancer patients compared to healthy control subjects (Marchesi et al., 2011; Chen et al., 2012; Kostic et al., 2012; Wu et al., 2013; Ahn et al., 2013; Zackular et al., 2014; Mira-Pascual et al., 2015; Thomas et al., 2016; Xu & Jiang, 2017; Gao et al., 2017) .
Among nine adenoma studies listed here, only three reported associations of adenomatous growth with Fusobacterium (McCoy et al., 2013; Goedert et al., 2015; Xu & Jiang, 2017) . McCoy et al., observed that Fusobacterium abundance was significantly higher in adenomas as compared to non-adenoma samples. In their study, a high level of Fusobacterium increases the chance of finding adenoma by 3.5 fold. Moreover, a positive correlation between Fusobacterium presence and cytokine levels was reported in the adenoma cohort. Specifically, a significant association between the levels of TNF-α, a cell signaling protein involved in systemic inflammation, and the abundance Fusobacterium level was reported (McCoy et al., 2013) . On the other hand, the other two studies reported a lack of Fusobacterium enrichment in the adenoma group (Goedert et al., 2015; Xu & Jiang, 2017) .
Another study also reported no significant change in the abundance of Fusobacterium in the advanced and non-advanced adenoma group as compared to colonoscopically healthy control adults (Amitay et al., 2017) . In our polyp cohort, Fusobacterium only showed a marginal decrease of its abundance in the biopsy, stool, and rectal swabs. It is possible that the pathways of polypogenesis are different from that of carcinogenesis and may depend on the invasiveness of the polyps which may, in turn, be reflected in observed discrepancies of association of Fusobacterium abundance. Additionally, the different experimental and analytical pipelines among the studies could be confounding this observation. A recent article that reviewed ninety original scientific published articles about Fusobacterium and its relationship with CRC in human, animal, and in vitro studies suggests that F. nucleatum can have a procarcinogenic effect for CRC which is probably is a result of triggering oncogenic and inflammatory pathways and alteration of the tumor immune environment (Hussan et al., 2017) .
Bacteroides:
Bacteroides species are butyrate-producing bacteria. Butyrate is a short chain fatty acid that has been shown to be effective in preventing inflammation through regulatory T-cells and controls proinflammatory cytokine expression (Cushing et al., 2015; Furusawa et al., 2013; Chang et al., 2014) . This short chain fatty acid is also a histone deacetylase inhibitor and has a role in preventing colonic tumors and promoting normal cell proliferation, differentiation, and apoptosis. Additionally, butyrate modulates the Wnt signaling pathway involved in the development of colorectal cancer (Malcomson et al., 2015) . Many
Bacteroides species have been isolated from human stool. Bacteroides fragilis (B. fragilis) is the most common Bacteroides species found in clinical specimens, and it has been reported to have virulent properties in some instances. Bacteroides becomes a part of the intestinal microbiota early in life as it can pass from mother to the child during the vaginal birth (Reid, 2004) . B.
fragilis is generally considered to be a beneficial bacterium, but it can be pathogenic if it escapes from the gut to other body sites such as the abdomen, brain, liver, and lungs (Wexler, 2007) .
Among the studies listed in Table S12 , there are reports of both decrease and increase of this genus in the CRC and adenoma cohorts with respect to the control groups. The number of studies detecting a higher abundance of Bacteroides in the cancer states are higher than the number of studies observing lower abundance of this genus (Chen et al., 2012; Wu et al., 2013; Zackular et al., 2014; Mira-Pascual et al., 2015; Thomas et al., 2016; Xu & Jiang et al., 2017; Gao et al., 2017; Yoon et al., 2017) .
However, for the adenoma cohorts, almost half detected enrichment and half reported depletion of Bacteroides in the adenoma state (Shen et al., 2010; Brim et al., 2013; Zackular et al., 2014; Yoon et al., 2017) . There is even one study that reported both decrease and increase of Bacteroides taxa in the adenoma state which can be because of the differences in the subtaxa (Goedert et al., 2015) . In our polyp dataset, all detected Bacteroides genera were higher in the polyp-Y group than polyp-N. As many different species and strains with potentially different functionalities can exist in the same genus, it is not that surprising that some of the Bacteroides taxa were decreased while others were increased in the disease state.
Enterotoxigenic Bacteroides fragilis: Enterotoxigenic B. fragilis (ETBF) is a virulent bacterium that produces a toxin named fragilysin or B. fragilis toxin (BFT). BFT can stimulate both inflammatory responses and cell proliferation. The inflammatory effect of BFT occurs through activating the nuclear factor kappa B which stimulates inflammatory mediators.
These mediators promote inflammation which is a risk factor for CRC (Sears et al., 2009; Shiryaev et al., 2013) . The proliferation effect of ETBF occurs through activating the Wnt/ β-catenin signaling pathway which increases cell proliferation (Sokol et al., 1999) . In the APC minus mouse model, Wu et al., showed that ETBF could promote tumorigenesis and increases the chance of colon adenoma and tumor formation in mice colonized with ETBF compared to control mice (Wu et al., 2009 ). Tumorigenesis effect of ETBF can also occur through other pathways such as activating STAT3, inducing IL-17 cytokine, and inducing spermine oxidase-dependent reactive oxygen species (ROS) production which causes DNA damage (Tosolini et al., 2011; Goodwin et al., 2011) . These studies suggest that there is a link between bacterial antigens, virulence factors, colon adenomas, and CRC. In our polyp dataset, the level of B. fragilis showed a reduction in the polyp-Y group. Thus, our study does not support B. fragilis playing a role in the polypogenesis pathway.
Blautia:
Blautia is a butyrate-producing bacterium that belongs to the Firmicutes phylum and Clostridial order. Most butyrate producers in the human colon belong to the Firmicutes phylum and in particular the clostridial clusters IV and XIVa (Louis and Flint, 2009; Van den Abbeele et al., 2013; Vital et al., 2014) . Blautia is known to digest complex carbohydrates, and an abundance of these bacteria is a strong indication of a healthy gut. As such, it is usually reported that the abundance of Blautia decreases in colorectal cancer patients as compared to the healthy control individuals (Chen et al., 2012; Goedert et al., 2015; Xu & Jiang, 2017; Yoon et al., 2017) . However, there are also reports of an increased abundance of this genus in the disease state (Wu et al., 2013; Mira-Pascual et al., 2015; Goedert et al., 2015; Yoon et al., 2017) .
In the polyp dataset, two different OTUs were assigned as Blautia in the biopsy samples that were significantly lower in the polyp-Y group compared to the polyp-N group. In stool samples and rectal swabs, there were two OTUs classified as Blautia, and they were higher in the polyp-Y group. Based on these observations, Blautia was decreased in the CRC state, but in the adenoma state either increases or decreases can be seen. Differential abundance may depend on whether the adenoma is benign or aggressive suggesting that the potential effect of strains of this genus on the polyposis or carcinogenesis pathways may be different. As we did not have additional detailed clinical information about the patients with the polyps, we could not further clarify the reason behind this pattern in different sample types.
Roseburia: Roseburia spp. are commensal bacteria that produce short-chain fatty acids, particularly butyrate which affects colonic motility and immunity maintenance and has anti-inflammatory properties. Depletion in Roseburia spp. abundance may affect various metabolic pathways and be associated with several diseases including irritable bowel syndrome, obesity, type 2 diabetes, nervous system conditions, and allergies. Roseburia spp. could also serve as probiotics for the restoration of a beneficial microbiota (Tamanai-Shacoori et al., 2016) . As Roseburia produces large amounts of butyrate by fermenting dietary carbohydrates, it may be critical for the control of inflammatory processes, especially in the colon (Louis et al., 2010; Louis et al., 2014; Pryde et al., 2002; Tamanai-Shacoori et al., 2016) .
Two of the seventeen studies reported enrichment of Roseburia in CRC samples, and two other studies showed depletion of this taxon in the cancer group (Marchesi et al., 2011; Thomas et al., 2016; Chen et al., 2012; Wu et al., 2013) . None of the adenoma studies we investigated showed changes in Roseburia taxa. In our polyp dataset, we did detect a decrease in the abundance of this taxon in biopsy samples and an increase in abundance in the swab and fecal samples of the polyp-Y group, although these changes were not statistically significant. prausnitzii levels were decreased in IBD patients compared with healthy control controls (Yang et al., 2008) . Three of the studies listed in Table S12 found that Faecalibacterium spp. were increased in adenoma subjects (Shen et al., 2010; Brim et al., 2013; Yoon et al., 2017) and Marchei et al. reported an increase of this genus in CRC cases (Marchesi et al., 2011) . Chen et al. reported
an increase of Faecalibacterium in CRC tissue while they found a decrease of this taxon in the swab samples (Chen et al., 2012) .
Four other studies demonstrated a decrease of Faecalibacterium in the CRC group (Wu et al., 2013; Xu & Jiang, 2017; Gao et al., 2017; Yoon et al., 2017) . In our polyp dataset, biopsies and stool samples had a higher abundance of F. prausnitzii. However, the swabs showed a lower abundance of this taxon. Thus, we did not find a consistent pattern for the change of F. prausnitzii with respect to adenoma and CRC based on these studies.
